The Impact and Evaluation of Immune Checkpoint Inhibitors on Clinical Survival in Patients with Advanced Osteosarcoma: A Systematic Review and Meta-Analysis.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Osteosarcoma is an aggressive bone cancer primarily affecting children and adolescents, with low survival rates in advanced stages. A systematic review and meta-analysis were conducted following PRISMA guidelines to evaluate the impact of ICIs on survival and toxicity in advanced osteosarcoma. ICIs show potential in treating advanced osteosarcoma but are associated with significant toxicity and uncertain survival benefits. Further research is needed to define their role and identify biomarkers for predicting response. Close monitoring for adverse events is essential.